CoChat

The causes and consequences of Alzheimer's disease: phenome-wide evidence from mendelian randomization

Open access

Published version of a preprint

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) has no proven causal and modifiable risk factors, or effective interventions. We report a phenome-wide association study (PheWAS) of genetic liability for AD in 334,968 participants of the UK Biobank study, stratified by age. We also examined the effects of AD genetic liability on previously implicated risk factors. We replicated these analyses in the HUNT study. PheWAS hits and previously implicated risk factors were followed up in a Mendelian randomization (MR) framework to identify the causal effect of each risk factor on AD risk. A higher genetic liability for AD was associated with medical history and cognitive, lifestyle, physical and blood-based measures as early as 39 years of age. These effects were largely driven by the APOE gene. The follow-up MR analyses were primarily null, implying that most of these associations are likely to be a consequence of prodromal disease or selection bias, rather than the risk factor causing the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-32183-6

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design for the phenome-wide association study of Alzheimer's disease genetic liability and follow-up Mendelian randomization of identified phenotypes on Alzheimer‘s disease. Diagram (A) describes our study design when conducting a phenome-wide association study, and diagram (B) describes our study design when using Mendelian randomization. In A, the polygenic risk score for Alzheimer's disease may either have a downstream causal effect on the trait (e.g., body mass index), or it may affect the trait through pathways other than through Alzheimer's disease (i.e., pleiotropic effects). Diagram (B) describes our follow-up analysis using Mendelian randomization to establish the causality and directionality of the observed associations. In B, we test the hypothesis that the trait (e.g., body mass index) causally affects liability to Alzheimer's disease, provided that the conditions (i), (ii), and (iii) are satisfied. The polygenic risk score for the trait of interest is a valid instrument in that (i) the single nucleotide polymorphisms for a trait are strongly associated with the trait they proxy (relevance), (ii) there are no confounders of the single nucleotide-outcome relationship (independence), and (iii) the single nucleotide polymorphisms only affect the outcome via their effects on the trait of interest (exclusion restriction).
Fig. 1 Study design for the phenome-wide association study of Alzheimer's disease genetic liability and follow-up Mendelian randomization of identified phenotypes on Alzheimer‘s disease. Diagram (A) describes our study design when conducting a phenome-wide association study, and diagram (B) describes our study design when using Mendelian randomization. In A, the polygenic risk score for Alzheimer's disease may either have a downstream causal effect on the trait (e.g., body mass index), or it may affect the trait through pathways other than through Alzheimer's disease (i.e., pleiotropic effects). Diagram (B) describes our follow-up analysis using Mendelian randomization to establish the causality and directionality of the observed associations. In B, we test the hypothesis that the trait (e.g., body mass index) causally affects liability to Alzheimer's disease, provided that the conditions (i), (ii), and (iii) are satisfied. The polygenic risk score for the trait of interest is a valid instrument in that (i) the single nucleotide polymorphisms for a trait are strongly associated with the trait they proxy (relevance), (ii) there are no confounders of the single nucleotide-outcome relationship (independence), and (iii) the single nucleotide polymorphisms only affect the outcome via their effects on the trait of interest (exclusion restriction).CC BY · PubMed Central
Fig. 2 Forest plot showing the effect estimates for the association between the polygenic risk score for Alzheimer’s disease (including the APOE region) and physical measures. Legends at the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. There is evidence that the polygenic risk score for Alzheimer’s disease is related to physical measures in older but not younger participants. This suggests that Alzheimer’s disease causes these changes rather than vice versa.
Fig. 2 Forest plot showing the effect estimates for the association between the polygenic risk score for Alzheimer’s disease (including the APOE region) and physical measures. Legends at the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. There is evidence that the polygenic risk score for Alzheimer’s disease is related to physical measures in older but not younger participants. This suggests that Alzheimer’s disease causes these changes rather than vice versa.CC BY · PubMed Central
Fig. 3 Forest plot showing the effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region), cognitive and brain-related measures. Legends at the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. *Effect estimates were derived from ordered logistic models, and effect estimates are on the log-odds scale. We found evidence that the polygenic risk score for Alzheimer’s disease is related to some cognitive measures in all age ranges examined. This may suggest a bidirectional relationship between cognitive measures and Alzheimer’s disease.
Fig. 3 Forest plot showing the effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region), cognitive and brain-related measures. Legends at the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. *Effect estimates were derived from ordered logistic models, and effect estimates are on the log-odds scale. We found evidence that the polygenic risk score for Alzheimer’s disease is related to some cognitive measures in all age ranges examined. This may suggest a bidirectional relationship between cognitive measures and Alzheimer’s disease.CC BY · PubMed Central
Fig. 4 Forest plot showing the effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and biological measures. Legends on the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The UK Biobank included an age-dependent increase in the effect of the polygenic risk score on blood-based measures. This may indicate that blood-based markers may be causal in the development of Alzheimer’s disease.
Fig. 4 Forest plot showing the effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and biological measures. Legends on the bottom of each graph indicate age tertiles. Each tertile consists of 111,656 participants, ordered by age. Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The UK Biobank included an age-dependent increase in the effect of the polygenic risk score on blood-based measures. This may indicate that blood-based markers may be causal in the development of Alzheimer’s disease.CC BY · PubMed Central
Fig. 5 Forest plot showing the age-stratified effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and physical measures in UK Biobank (diamond markers) and HUNT (replication sample, circle markers). Legends at the bottom of each graph indicate age tertiles in both cohorts. The colors represent blue, the youngest age tertile (39–53 years); red; middle age tertile (53–62 years); green, the oldest age tertile (62–72 years). Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The UK Biobank analyses included 9,043–111,485 participants in each tertile. The HUNT analyses included 7,267–18,307 participants in each age tertile. The confidence intervals are smaller in UK Biobank due to the larger sample size of the cohort compared to HUNT.
Fig. 5 Forest plot showing the age-stratified effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and physical measures in UK Biobank (diamond markers) and HUNT (replication sample, circle markers). Legends at the bottom of each graph indicate age tertiles in both cohorts. The colors represent blue, the youngest age tertile (39–53 years); red; middle age tertile (53–62 years); green, the oldest age tertile (62–72 years). Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The UK Biobank analyses included 9,043–111,485 participants in each tertile. The HUNT analyses included 7,267–18,307 participants in each age tertile. The confidence intervals are smaller in UK Biobank due to the larger sample size of the cohort compared to HUNT.CC BY · PubMed Central
Fig. 6 Forest plot showing the age-stratified effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and blood-based biomarker measures in UK Biobank (diamond markers) and HUNT (replication sample, circle markers). Legends at the bottom of each graph indicate age tertiles in both cohorts. The colors represent blue, the youngest age tertile (39–53 years); red; middle age tertile (53–62 years); green, the oldest age tertile (62–72 years). Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The HUNT analyses included 7,267–18,307 participants for these measures. The UK Biobank analyses included 108,095–108,391 participants for blood-based biomarkers. The confidence intervals are smaller in UK Biobank due to the larger sample size of the cohort compared to HUNT.
Fig. 6 Forest plot showing the age-stratified effect estimates for the association between the polygenic score for Alzheimer’s disease (including the APOE region) and blood-based biomarker measures in UK Biobank (diamond markers) and HUNT (replication sample, circle markers). Legends at the bottom of each graph indicate age tertiles in both cohorts. The colors represent blue, the youngest age tertile (39–53 years); red; middle age tertile (53–62 years); green, the oldest age tertile (62–72 years). Effect estimates represent an SD change in the phenotype per 1 unit increase in the standardized polygenic risk score for Alzheimer’s disease. Error bars represent 95% confidence intervals. All statistical tests were two-sided. The HUNT analyses included 7,267–18,307 participants for these measures. The UK Biobank analyses included 108,095–108,391 participants for blood-based biomarkers. The confidence intervals are smaller in UK Biobank due to the larger sample size of the cohort compared to HUNT.CC BY · PubMed Central
Fig. 7 Association of Alzheimer’s disease polygenic risk score with the phenome, and estimated effect of each phenotype using Mendelian randomization. These findings showed evidence of association in the MR framework, following a correction for multiple testing using a strategy controlling for the false discovery rate. + and – indicate the direction of the coefficient for phenotypes associated with Alzheimer’s disease using two-sample MR. X represents associations that were consistent with the null.
Fig. 7 Association of Alzheimer’s disease polygenic risk score with the phenome, and estimated effect of each phenotype using Mendelian randomization. These findings showed evidence of association in the MR framework, following a correction for multiple testing using a strategy controlling for the false discovery rate. + and – indicate the direction of the coefficient for phenotypes associated with Alzheimer’s disease using two-sample MR. X represents associations that were consistent with the null.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Research works printed but not linked: 1

  1. Smit, R. A. J., Trompet, S., Dekkers, O. M., Jukema, J. W. & Cessie, S. Survival bias in Mendelian randomization. Studies 30, 813–816 (2019).

Cited by

See all 72

Metadata

Authors
Korologou-Linden, R., Bhatta, L., Brumpton, B. M., Howe, L. D., Millard, L. A. C., Kolaric, K., Ben-Shlomo, Y., Williams, D. M., Smith, G. D., Anderson, E. L., Stergiakouli, E., & Davies, N. M.
Affiliations
  • Norwegian University of Science and Technology (NO)
  • University of Bristol (GB)
  • Karolinska Institutet (SE)
Venue
Nature Communications
Published
2022-08-11
Volume
13
Issue
1
Pages
4726-4726
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4290803778
Cited by
71
References
84
Citations by year
2026: 11 · 2025: 17 · 2024: 18 · 2023: 13 · 2022: 7
FWCI
9.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Explore Bristol Research (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
  • Vanderbilt University
  • University of Miami
  • University of Pennsylvania
  • Stiftelsen Kristian Gerhard Jebsen
  • Case Western Reserve University
  • Norges Teknisk-Naturvitenskapelige Universitet (295989)
  • Wellcome Trust (MC_UU_00011/1, 082604/2/07/Z, 215193, 295989, 082604, 215193/Z18/Z)
  • Broad Institute (U54HG003067)
  • Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease
  • National Alzheimer's Coordinating Center (U01AG016976)
  • University of Bristol (MC_UU_12013/1, MC_UU_00011/1, MC_UU_12013/9)
  • Agence Nationale de la Recherche (ANR-11-LABX-0009)
  • Institut National de la Santé et de la Recherche Médicale
  • University of Toronto
  • Helse Midt-Norge
  • Norges Forskningsråd (295989, ES/N000757/1)
  • St. Olavs Hospital Universitetssykehuset i Trondheim
  • National Institutes of Health (HHSN268201100012C, n01ag12100-57-0-2, HHSN268201100008C, HHSN26820- 1100005C, HHSN268201100007C, HHSN268201100011C, HHSN268201100010C)
  • Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet
  • Medical Research Council (MC_UU_12013/1, MC_UU_12013/9, MC_UU_12013, MR/M020894, MCUU12013/1, MR/M020894/1, MR/P014437/1, MC_PC_17228, MC_UU_00011/1, MC_UU_00011, MC_UU_12013/9)
  • Economic and Social Research Council (ES/N000757/1, MC_UU_00011/1)
  • Faculty of Medicine and Health, University of Sydney
  • Norwegian Institute of Public Health
  • National Institute on Aging (U01AG049505, N01-AG12100, U01AG016976, U01AG032984, AG033193, UF1AG047133, U01AG049506, AG032984, U01AG049507, U01AG049508, R01AG033193, U54AG052427, U24AG041689, U24AG021886)
  • National Heart, Lung, and Blood Institute (HHSN268201 100012C, HHSN268201100007I, HHSN268201100007C, HHSN2682 01100008C, HH-SN-268201100006C, HHSN268201100011C, HHSN2682011-00005I, HL-105756, HHSN2682011-­00009I, HHSN268201100005C, HHSN268201100005G, HHSN268201100010C, HHSN268201100011I, HHSN26820 1100009C, R01HL105756, HHSN2682011-00008I, AG033193, RC2HL102419)
  • National Human Genome Research Institute (U54HG003067, HHSN268201100010C, U54HG003079, HG003273, U54HG003273, HHSN268201100011C, HHSN268201100012C, HHSN268201100007C, HHSN268201100005C, HHSN268201100008C)
  • U.S. National Library of Medicine
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, genetic susceptibility, apolipoprotein E, causal risk factors, phenome-wide association study, Mendelian randomization, selection bias, cognitive function, lifestyle factors, blood biomarkers, early age of onset
MeSH terms
Phenomics, Alzheimer Disease, Humans, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The causes and consequences of Alzheimer's disease: phenome-wide evidence from mendelian randomization. https://app.cochat.ai/papers/10.1038/s41467-022-32183-6
The paper
Korologou-Linden, R., Bhatta, L., Brumpton, B. M., Howe, L. D., Millard, L. A. C., Kolaric, K., Ben-Shlomo, Y., Williams, D. M., Smith, G. D., Anderson, E. L., Stergiakouli, E., & Davies, N. M. (2022). The causes and consequences of Alzheimer's disease: phenome-wide evidence from mendelian randomization. Nature Communications. https://doi.org/10.1038/s41467-022-32183-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.